Rosas S, Schallmo M, Gowd AK, Akelman MR, Luo TD, Emory CL, Plate JF. Dermatomyositis and polymyositis in total hip arthroplasty. World J Orthop 2021; 12(6): 395-402 [PMID: 34189077 DOI: 10.5312/wjo.v12.i6.395]
Corresponding Author of This Article
Samuel Rosas, MD, PhD, Doctor, Department of Orthopedic Surgery, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC 27101, United States. srosas@wakehealth.edu
Research Domain of This Article
Orthopedics
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Orthop. Jun 18, 2021; 12(6): 395-402 Published online Jun 18, 2021. doi: 10.5312/wjo.v12.i6.395
Dermatomyositis and polymyositis in total hip arthroplasty
Samuel Rosas, Michael Schallmo, Anirudh Krishna Gowd, Matthew Reynolds Akelman, T David Luo, Cynthia Lynn Emory, Johannes Frank Plate
Samuel Rosas, Anirudh Krishna Gowd, Matthew Reynolds Akelman, T David Luo, Cynthia Lynn Emory, Johannes Frank Plate, Department of Orthopedic Surgery, Wake Forest School of Medicine, Winston Salem, NC 27101, United States
Michael Schallmo, Department of Orthopedic Surgery, Atrium Healthcare, Charlotte, NC 28203, United States
Author contributions: All of the authors have contributed to the final manuscript encompassed herein.
Institutional review board statement: Retrospective, HIPAA compliant database does not require IRB review.
Informed consent statement: The written informed consent was waived.
Conflict-of-interest statement: None of the authors report a conflict of interest with this paper.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at srosas@wakehealth.edu
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Samuel Rosas, MD, PhD, Doctor, Department of Orthopedic Surgery, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC 27101, United States. srosas@wakehealth.edu
Received: January 3, 2021 Peer-review started: January 3, 2021 First decision: March 1, 2021 Revised: March 22, 2021 Accepted: May 20, 2021 Article in press: May 20, 2021 Published online: June 18, 2021 Processing time: 158 Days and 17.5 Hours
ARTICLE HIGHLIGHTS
Research background
There is a paucity of data evaluating patients with dermatomyositis (DM) and polymyositis (PM) undergoing total hip arthroplasty (THA).
Research motivation
To compare and contrast the outcomes of patients undergoing THA with DM and PM vs a matched control without inflammatory arthropathies.
Research objectives
To elucidate whether patients with DM and PM have increased risk of complications and greater 90-d costs when undergoing THA compared to controls.
Research methods
A retrospective case control was performed based on the medicare data.
Research results
Patients with DM and PM had increased rates of pneumonia [odds ratio (OR) 1.45, P < 0.001] and pulmonary embolism (OR 1.46, P = 0.035) and decreased hematoma risks (OR 0.58, P = 0.00). 90-d costs were on average $1411 greater for those with idiopathic inflammatory myopathies (IIM) yet not significantly different (P = 0.034).
Research conclusions
Patients with IIM have an increased 90-d rate of pneumonia and pulmonary embolism concomitant with a decreased hematoma rate consistent with their pro-coagulatory state.
Research perspectives
It is important to evaluate deep vein thrombose prophylaxis and respiratory status in those undergoing THA with DM or PM.
